Substituted r-biarylbutyric or 5-biarylpentanoic acids and derivatives as matrix metalloprotease inhibitors

Inhibitors for matrix metalloproteases, pharmaceutical compositions containing them, and a process for using them to treat a variety of physiological conditions. The presently claimed compounds have the generalized formula in which each T represents a substituent group; x is 0, 1, or 2; D represents delta is 0 or 1; U' represents O, S, or N, with the proviso that when U' is N, then delta =0, and when U' is O or S, then delta =1; R14 is any of a variety of substituent groups; and G represents M, in which M represents -CO2H, -CON(R11)2, or -CO2R12, R11 represents H or an alkyl group, R12 represents an alkyl group, and R13 represents any of the side chains of the 19 noncyclic naturally occurring amino acids; and pharmaceutically acceptable salts thereof.